FRONTIER1:一项部分随机化2期研究评估FVIIIa模拟物Mim8的安全性、药代动力学和药效学
FRONTIER1的2期多剂量递增部分纳入42例伴或不伴FVIII抑制物的A型血友病患者,分5个队列,其中队列3和4按1:1随机分配至每周或每4周给药。Mim8耐受性良好,仅1例严重治疗中出现的不良事件(焦虑相关胸痛)判定与Mim8无关;药代/药效学支持每周至每月给药方案,数据支持Mim8继续临床开发并已进入扩展期。
要点
- Mim8在A型血友病患者中耐受性良好,仅1例严重TEAE(焦虑相关胸痛)判定与Mim8无关。
- TEAE的数量、因果关系、类型或严重程度未见剂量依赖性。
- 药代/药效学特征支持每周至每月给药方案,数据支持继续临床开发。
核心结论
- 这些数据支持Mim8的继续临床开发,FRONTIER1已进入扩展期。
- Mim8在A型血友病患者中耐受性良好,药代/药效学特征支持每周至每月给药方案。
研究设计与样本
- FRONTIER1的2期多剂量递增部分为部分随机化研究,共纳入42例伴或不伴FVIII抑制物的A型血友病患者。
- 42例参与者分配至5个队列,队列3和4的参与者分别按1:1随机分配至每周或每4周给药。
- 42例参与者中4例(9.5%)在研究入组前有FVIII抑制物。
- 主要终点为治疗中出现的不良事件(TEAE),药代和药效学分别通过Mim8血浆浓度和凝血酶生成评估。
- 安全性及药效学参数另在一个接受emicizumab治疗的探索性队列中评估。
主要发现
- Mim8耐受性良好,发生1例严重TEAE(焦虑相关胸痛),判定与Mim8无关。
- TEAE的数量、因果关系、类型或严重程度未见剂量依赖性。
- 药代/药效学特征支持每周至每月给药方案。
- 除最低剂量队列外,少数参与者发生需要治疗的出血:队列2和队列3各1例,队列5有3例。
关键数值与推荐
- 主要终点为TEAE;药代和药效学分别通过Mim8血浆浓度和凝血酶生成评估;探索性疗效通过需要治疗的出血次数评估。
- 42例参与者中4例(9.5%)在研究入组前有FVIII抑制物。
- 队列3和4的参与者分别按1:1随机分配至每周或每4周给药。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mim8 (denecimig) is a factor VIII (FVIII) mimetic bispecific antibody in development for the treatment of hemophilia. Data from the phase 1 part of FRONTIER1 (EudraCT: 2019-000465-20, NCT04204408, and NN7769-4513) suggested that Mim8 was well tolerated in healthy participants and exhibited pharmacokinetic (PK) properties consistent with dose proportionality. OBJECTIVES: The partially randomized, phase 2, multiple ascending dose (MAD) part of FRONTIER1 aimed to evaluate the safety, PK, pharmacodynamics (PD), and exploratory efficacy of Mim8 in participants with hemophilia A with or without FVIII inhibitors. METHODS: The MAD part of FRONTIER1 consisted of 42 participants, assigned to 5 cohorts, with participants in cohorts 3 and 4 randomized 1:1 to dosing weekly or every 4 weeks, respectively. Four of the 42 participants (9.5%) had FVIII inhibitors prior to study enrolment. The primary endpoint was treatment-emergent adverse events (TEAEs). PK and PD were evaluated by Mim8 plasma concentration and thrombin generation, respectively. Exploratory efficacy was assessed via the number of treated bleeds. Safety and PD parameters were also evaluated from an exploratory cohort treated with emicizumab. RESULTS: Mim8 was well tolerated, with 1 serious TEAE (anxiety-related chest pain) deemed unrelated to Mim8. There was no dose dependency on the number, causality, type, or severity of TEAEs. PK/PD properties supported weekly to monthly dosing approaches, and few participants experienced treated bleeds beyond the lowest dose cohort (1 in cohorts 2 and 3, and 3 in cohort 5). CONCLUSION: These data support the continued clinical development of Mim8, and FRONTIER1 has proceeded onto an extension phase.
引用
- Lentz SR, Chowdary P, Gil L, et al. FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic. J Thromb Haemost. 2023. PMID: 38142846. doi:10.1016/j.jtha.2023.12.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。